John Stanford

@bradloncar @JMaraganore We're trying over @incub8coalition! One thing we all need to do more is talk about our failures and what our wins mean for patients (not just P&Ls / portfolios)

@JMaraganore I think biotech needs an advocacy organization that is focused on improving our industry’s (and science’s) image with the general public. It would make everything else, including the lobbying work, so much easier if we had more public support.

I applaud formation of this new advocacy group! One size doesn’t fit all, and many biotechs have unique policy needs as compared to big pharma. Bravo!

A lot of talk about how @OpenAI @ChatGPTapp gets stuff wrong, but I input the cheapest NC @BlueCrossNC #bronze #insurance plan into GPT and got this. Looks right to me.🧐

On today's #BiotechHangout, @ColonGraceE, @cngarabedian, @SamFazeli8, @MatteisPaul, @YaronWerber, and special guest @johnbstanford will cover policy: NDAA provisions & implications for biotech, industry trends & deals: big Monday w/ $1.85B in biotech financings – most in one day?, $XBI’s sustained momentum & positive signals, $LLY’s acquisitive strategy, plus Fosun+$PFE deal for oral GLP-1, conferences: #ASH2025 ($AZN, $LLY vs $ONC, $JNJ/$LEGN vs $GILD/ACLX, $GMAB, $TERN), #ESMOAsia25 ($BNTX, Zelgen, $GSK, & other ADCs), $CGON at #SUO25, plus other data: $DYN positive DMD data, obesity news ($GPCR, $WVE, Ascletis), Endpoints 100 takeaways & much more: x.com/i/spaces/1lpkq…

"What are we going to do from a national security perspective when China has the cure for diabetes?" @johnbstanford at last week's @PunchbowlNews fireside chat, stressing that when the U.S. falls behind in biotech, it poses a risk to our medical supply chains.

"Startups are being forced to make hard choices: shelve promising programs, pull back on trials or pivot away from entire classes of cutting-edge and potentially life-saving drugs." @johnbstanford in @BioSpace on why Congress must pass the EPIC Act. buff.ly/kHCSGZU

Last week, @johnbstanford joined @PunchbowlNews for a fireside chat on the future of medicine, stressing the need to sustain U.S. leadership in life sciences and boost investment in small biotechs developing lifesaving treatments.

"We want foreign investors coming to U.S.-based companies to develop drugs for the world." @johnbstanford spoke with @FierceBiotech at this year's @BIOConvention about supporting a robust U.S. life sciences sector.

Small molecule companies are "not the cool kid in the class anymore," @johnbstanford told @PharmaVoice. He outlines Incubate's survey findings on how the IRA, tariffs, and NIH cuts are shaking biotech CEOs confidence -- and what that means for Washington. buff.ly/sARIRwh

Good things come in small molecules. Fix the #pillpenalty. Happy Valentine’s Day! ❤️ 💊

Japan can be a biotech powerhouse. That's what we're working on.

#EX24Canada has kicked off in #Toronto with opening remarks from SBR Co-Executive Director @johnbstanford. Today's agenda is stacked with North America's leading voices in #smallbiz. #entrepreneurshipexchange

This is a “classic example of a market failure, with little to no incentive to invest in #AMR versus other promising therapeutics,” @johnbstanford explains. biospace.com/article/why-is…

@danprimack Well duh, the singularity doesn't want to call attention to itself.

No mention by anyone during the debate about AI, which will be a dominant economic/labor/culture/geopolitics story during the next four years.

@minakimes No room on the broom?

Top 5 books I enjoy reading to my 8 month old: 1. Chicka Chicka Boom Boom (legitimately funny) 2. Pout Pout Fish 3. Giraffes Can't Dance 4. I Want My Hat Back 5. Corduroy

@sciencescanner What if...and hear me out...we take biotech and we, you know, reverse it? TECHBIO!!!!

@AlexHarding7 @EvercoreISI Not to mention the ancillary effects: other drugs in that class losing formulary placement in commercial, change in NPV calculations for investors, particularly for small molecule...feels like those polled are laser focused on "negotiated" company stock price only.

49% of investors in @EvercoreISI Josh Schimmer’s poll think the IRA price “negotiations” in 2024 will be a “non-event.” Who thinks that, in an election year, CMS is going to go soft on pharmas when it has latitude to set basically any price it wants?

@ryanmouquegolf Well no, you said 20ft short vs long. And I thought to myself, how many times have caddies / course pros / friends told me: leave it below the pin. So I disagreed. On a fast sloping (B2F) green, I would rather be 20 ft from hole putting through 10' of fairway than 20' above.

@johnbstanford Ur talking about putting from off the green after just slightly missing… I’m talking about a golfer coming up miles short vs having a 20ft putt above the hole…

🚨Pre Shot Routine🚨 Golfers... do want a bulletproof pre shot routine when you go out to play golf? Here are my absolute must dos if you want to have a tour quality pre shot routine 👊 🧵

@ryanmouquegolf So are we agreed it depends on what is more forgiving?

@johnbstanford How much control do I think golfers have of their ball to pick and choose where they are going to hit their shot? How come pros do t hit it where they want everytime?

@ryanmouquegolf Yeah, I guess I do? arccosgolf.com/blogs/communit… thesandtrap.com/forums/topic/9…

@johnbstanford U sure about that mate? Do u have facts to back up what ur saying?

@ryanmouquegolf Gotta disagree a bit here. W/ so many greens sloping back to front, throwing it beyond the pin (assuming like me you don't get a ton of spin) you're significantly increasing 3 putt chance. Just short of a front pin at the neck is a very safe play, usually leaving uphill putt.

- Approach Shot (Including Par 3s) Same as off the tee but now include the flag, as well as the front and back of the green. Pro Tip: Be long of front flags and short of back flags... 20ft long of a front flag is better than being 20ft short and chipping 🙂